cannabidiol hydroxyquinone: structure given in first source; an air oxidation product of cannabidiol; inhibits the hepatic microsomal drug-metabolizing enzymes of mice through the decrease of cytochrome P-450 content; RN given refers to (1R-trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11393311 |
| CHEMBL ID | 4635276 |
| CHEBI ID | 197014 |
| SCHEMBL ID | 13609377 |
| MeSH ID | M0199219 |
| Synonym |
|---|
| cbdhq |
| hu 331 |
| hu331 |
| cannabidiol hydroxyquinone |
| hu-331 |
| 137252-25-6 |
| 3-hydroxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylcyclohexa-2,5-diene-1,4-dione |
| CHEBI:197014 |
| 2,5-cyclohexadiene-1,4-dione, 3-hydroxy-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1r-trans)- |
| i7q196l4au , |
| unii-i7q196l4au |
| CCG-208732 |
| 2,5-cyclohexadiene-1,4-dione, 3-hydroxy-2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl- |
| SCHEMBL13609377 |
| HMS3649F22 |
| AKOS030241459 |
| J-006987 |
| Q3825917 |
| DTXSID10929758 |
| vce 004 |
| SR-01000946715-1 |
| sr-01000946715 |
| cannabidiol hydroxyquinone (cbdhq) |
| bdbm50541572 |
| CHEMBL4635276 , |
| FS-7319 |
| cannabidiol hydroxyquinone (cbdhq) 100 microg/ml in acetonitrile |
| cannabidiol hydroxyquinone (cbdhq) 1000 microg/ml in acetonitrile |
| Excerpt | Reference | Relevance |
|---|---|---|
| " A comparative in vivo study in mice has shown HU-331 to be less toxic and more effective than the commonly used doxorubicin." | ( HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Kogan, NM; Peters, M, 2007) | 0.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Topoisomerase II (Topo2) inhibitors in combination with cisplatin represent a common treatment modality used for glioma patients." | ( Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors. Galita, G; Kopa, P; Macieja, A; Majsterek, I; Pastwa, E; Poplawski, T, 2019) | 0.51 |
| Class | Description |
|---|---|
| prenylquinone | A quinone substituted by a polyprenyl-derived side-chain. Prenylquinones occur in all living cells. Due to their amphiphilic character, they are mainly located in biological membranes where they function as electron and proton carriers in the photosynthetic and respiratory electron transport chains. Some prenylquinones also perform more specialised roles sucy as antioxidants and enzyme cofactors. Prenylquinones are classified according to ring structure: the main classes are menaquinones, phylloquinones, ubiquinones and plastoquinones. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 10.5000 | 0.0000 | 0.9922 | 10.0000 | AID1657599 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleoplasm | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| cytosol | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| RNA polymerase II transcription regulator complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| chromatin | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| receptor complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1657599 | Agonist activity at GAL4-tagged PPARgamma (unknown origin) transiently expressed in HEK293T cells co-transfected with GAL4-tagged luc incubated for 6 hrs by dual luciferase reporter gene assay | 2020 | Journal of natural products, 05-22, Volume: 83, Issue:5 | The Oxidation of Phytocannabinoids to Cannabinoquinoids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (13.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (86.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||